Two trials of paclitaxel-coated devices to treat peripheral arterial disease have been halted in recent weeks due to reports the devices were tied to a higher mortality risk. Endovascular physician group VIVA is organizing a February meeting to discuss the issue. Two trials of paclitaxel-coated devices to treat peripheral arterial disease have been halted in recent weeks due to reports the devices were tied to a higher mortality risk. Endovascular physician group VIVA is organizing a February meeting to discuss the issue.
With concern over drug-eluting stents growing after a meta-analysis found a risk of patient death, two studies have been cancelled and a physician group has announced that a conference to discuss the issue is in the works.
The meta-analysis, published Dec. 6 in the Journal of the American Heart Association, reviewed data from 28 studies comparing...